Current understanding and management of medullary thyroid cancer

Oncologist

Volumn 18, Issue 10, 2013, Pages 1093-1100

  Roy, Madhuchhanda ^a   Chen, Herbert ^a   Sippel, Rebecca S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Familial medullary thyroid cancer (FMTC); Medullary thyroid cancer (MTC); Multiple endocrine neoplasia syndrome; Prophylactic surgery in MTC; RET proto oncogene; Serum calcitonin

Indexed keywords

AXITINIB; CABOZANTINIB; CALCITONIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; IMATINIB; MOTESANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; PROTEIN RET; RET PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FOLLOW UP; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HISTOLOGY; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; SIPPLE SYNDROME; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CARCINOMA, MEDULLARY; GENETICS; GERMLINE MUTATION; LYMPH NODE DISSECTION; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PATHOLOGY; THYROID NEOPLASMS;

CALCITONIN; CARCINOMA, MEDULLARY; GERM-LINE MUTATION; HUMANS; LYMPH NODE EXCISION; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84886011426     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0053     Document Type: Article

References (65)

1. Hundahl SA, Cady B, Cunningham MP et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. US and German Thyroid Cancer StudyGroupAnAmericanCollege of SurgeonsCommission on Cancer Patient Care Evaluation study Cancer 2000;89:202-217.
2. Thyroid Cancer Treatment (PDQ®). Medullary Thyroid Cancer. Available at http://www. cancer.gov/cancertopics/pdq/treatment/thyroid/ HealthProfessional/page7. Accessed July 29, 2013.
3. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575-1579.
4. Mulligan LM, Eng C, Healey CS et al. Specificmutations of the RET proto-oncogene are related to disease phenotype inMEN2A and FMTC. Nat Genet 1994;6:70-74.
5. Moline J, Eng C. Multiple endocrine neoplasia type 2: An overview. Genet Med 2011;13:755-764.
6. Hofstra RM, Landsvater RM, Ceccherini I et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-376.
7. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152-161.
8. Saad MF, Ordonez NG, Rashid RK et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319-342.
9. Dottorini ME, Assi A, SironiMet al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996;77:1556-1565.
10. Mure A, Gicquel C, Abdelmoumene N et al. Cushing's syndrome in medullary thyroid carcinoma. J Endocrinol Invest 1995;18:180-185.
11. Smallridge RC, Bourne K, Pearson BW et al. Cushing's syndrome due to medullary thyroid carcinoma: Diagnosis by proopiomelanocortin messenger ribonucleic acid in situ hybridization. J Clin Endocrinol Metab 2003;88:4565-4568.
12. Chang TC, Wu SL, Hsiao YL. Medullary thyroid carcinoma: Pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations. Acta Cytol 2005;49: 477-482.
13. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol 2000;22:351-358.
14. Chen H, Sippel RS, O'Dorisio MS et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010;39:775-783.
15. Kudo T, Miyauchi A, Ito Y et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 2007;17:635-638.
16. Boi F, Maurelli I, Pinna G et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:2115-2118.
17. Cohen R, Campos JM, Salaün C et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC) J Clin Endocrinol Metab 2000;85:919-922.
18. Barbet J, Campion L, Kraeber-Bodéré F et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-6084.
19. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
20. Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
21. Machens A, Dralle H. Pretargeted anti-carcinoembryonic-antigen radioimmunotherapy for medullary thyroid carcinoma. J Clin Oncol 2006:24: e37; author reply e38.
22. Giovanella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: Role ofCgAandCEAascomplementarymarkers. Int J Biol Markers 2008;23:129-131.
23. Mirallié E, Vuillez JP, Bardet S et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 2005;90:779-788.
24. Oudoux A, Salaun PY, Bournaud C et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007;92:4590-4597.
25. Giraudet AL, Vanel D, Leboulleux S et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007;92:4185-4190.
26. Ong SC, Schöder H, Patel SG et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007;48:501-507.
27. Tung WS, Vesely TM, Moley JF. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995;118:1024-1029, discussion 1029-1030.
28. Moore SW, Zaahl M. Familial associations in medullarythyroidcarcinomawith Hirschsprung disease: The role of the RET-C620 "Janus" genetic variation. J Pediatr Surg 2010;45:393-396.
29. Fialkowski EA, DeBenedetti MK, Moley JF et al. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg 2008;43:188-190.
30. Bütter A, Gagné J, Al-Jazaeri A et al. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: Mutation in C620 is associated with Hirschsprung's disease. J Pediatr Surg 2007;42: 203-206.
31. Donovan DT, Levy ML, Furst EJ et al. Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: A new variant. Henry Ford Hosp Med J 1989;37:147-150.
32. Verga U, Fugazzola L, Cambiaghi S et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 2003;59: 156-161.
33. O'Riordain DS, O'Brien T, Crotty TB et al. Multiple endocrine neoplasia type 2B:Morethan an endocrine disorder. Surgery 1995;118:936-942.
34. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
35. Frank-Raue K, Buhr H, DralleHet al. Long-term outcomein46genecarriers of hereditarymedullary thyroid carcinoma after prophylactic thyroidectomy: Impact of individual RET genotype. Eur J Endocrinol 2006;155:229-236.
36. Shepet K, Alhefdhi A, Lai N et al. Hereditary medullary thyroid cancer: Age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol 2013;20:1451-1455.
37. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: Recommendations for extent of node dissection. Ann Surg 1999;229:880-887, discussion 887-888.
38. Greenblatt DY, Elson D, Mack E et al. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg 2007;30:108-112.
39. Scollo C, Baudin E, Travagli JP et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88:2070-2075.
40. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 2007;31:1960-1965.
41. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. The Oncologist 2008;13:539-547.
42. Brierley J, Tsang R, Simpson WJ et al. Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-310.
43. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3466-3469.
44. Almeida MQ, Hoff AO. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 2012;24:229-234.
45. Wells SA, Gosnell JE, GagelRFet al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-772.
46. Robinson BG, Paz-Ares L, Krebs A et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-2671.
47. Wells SA, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, doubleblind phase III trial. J Clin Oncol 2012;30:134-141.
48. Cabozantinib approved for rare thyroid cancer. Cancer Discov 2013:3:OF7.
49. Hart CD, De Boer RH. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther 2013;6: 1-7.
50. Traynor K. Cabozantinib approved for advanced medullary thyroid cancer. Am J Health Syst Pharm 2013;70:88.
51. Ahmed M, Barbachano Y, Riddell A et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol 2011;165:315-322.
52. Lam ET, Ringel MD, Kloos RT et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-2330.
53. Carr LL, Mankoff DA, Goulart BH et al. Phase II study of daily sunitinib in FDG-PET-positive, iodinerefractory differentiated thyroid cancer and meta-static medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-5268.
54. Schlumberger MJ, Elisei R, Bastholt L et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-3801.
55. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-4713.
56. KunnimalaiyaanM, ChenH. Tumorsuppressor role ofNotch-1signaling in neuroendocrine tumors. The Oncologist 2007;12:535-542.
57. Ning L, Greenblatt DY, KunnimalaiyaanMet al. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. The Oncologist 2008;13:98-104.
58. Vaccaro A, Chen H, Kunnimalaiyaan M. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs 2006;17:849-853.
59. KunnimalaiyaanM, VaccaroAM, NdiayeMAet al. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007;6:1151-1158.
60. Kunnimalaiyaan M, Ndiaye M, Chen H. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 2006;140:1009-1014.
61. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA et al. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006;281:39819-39830.
62. Adler JT, Cook M, Luo Y et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther 2009;8: 914-920.
63. Adler JT, Hottinger DG, Kunnimalaiyaan M et al. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitorsandlithium chloride. J Surg Res 2010;159:640-644.
64. Cook MR, Luo J, NdiayeMet al. Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer. Am J Surg 2010;199:315-318, discussion 318.
65. Truong M, Cook MR, Pinchot SN et al. Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol 2011;18:1506-1511.